| 恩替卡韦治疗失代偿期乙型肝炎肝硬化临床观察 |
| |
| 引用本文： | 祝卫东,陈良云,陈俊飞,朱跃红,衣展华,丁锷,赵卫峰. 恩替卡韦治疗失代偿期乙型肝炎肝硬化临床观察[J]. 肝脏, 2010, 15(2): 87-89 |
| |
| 作者姓名： | 祝卫东 陈良云 陈俊飞 朱跃红 衣展华 丁锷 赵卫峰 |
| |
| 作者单位： | 江苏省常熟市第二人民医院传染病分院传染科,215500;苏州大学附属第一医院传染科 |
| |
| 摘 要： | 目的研究恩替卡韦治疗失代偿期乙型肝炎肝硬化96周的病毒学应答和临床疗效。方法 36例失代偿期乙型肝炎肝硬化患者在内科综合治疗基础上口服ETV0.5mg/d。疗程中监测患者生化学指标、凝血功能、HBVDNA载量,并观察有无不良反应的发生。结果 1）32例患者（88.88%）各项指标得到明显改善,疗程中无明显不良反应发生。2例（5.56%）总胆红素曾一度上升,经治后恢复正常;1例（2.78%）出现消化道出血死亡;1例（2.78%）出现原发性肝癌死亡。2）患者12周、24周、48周、96周时HBVDNA阴转率分别为37.14%（13/35）、68.57%（24/35）、88.24%（30/34）、91.18%（31/34）（P〈0.0001）。3）患者基线、12周、24周、48周、96周时Child-Pugh积分分别为10.0±1.9、8.7±1.8、7.6±1.8、6.4±1.1、6.4±1.1（P〈0.0001）。结论恩替卡韦治疗失代偿期乙型肝炎肝硬化患者有较好病毒学应答和Child-Pugh积分改善。
|
| 关 键 词： | 乙型肝炎肝硬化 失代偿期 恩替卡韦 |
Efficacy of entecavir in patients with hepatitis B virus-related decompensated cirrhosis |
| |
| ZHU Wei-dong,CHEN Liang-yun,CHEN Jun-fei,ZHU Yue-hong,YI Zhan-hua,DING E,ZHAO Wei-feng. Efficacy of entecavir in patients with hepatitis B virus-related decompensated cirrhosis[J]. Chinese Hepatology, 2010, 15(2): 87-89 |
| |
| Authors: | ZHU Wei-dong CHEN Liang-yun CHEN Jun-fei ZHU Yue-hong YI Zhan-hua DING E ZHAO Wei-feng |
| |
| Affiliation: | ZHU Wei-dong,CHEN Liang-yun,CHEN Jun-fei,ZHU Yue-hong,YI Zhan-hua,DING E,ZHAO Wei-feng Department of Infectious Disease,Changshu No.2 People's Hospital,Jiangsu 215500,China |
| |
| Abstract: | Objective To investigate the effects of 96-week entecavir(ETV) therapy on viral suppression and hepatic function in patients with hepatitis B virus(HBV)-related decompensated cirrhosis.Methods Thirty-six patients with decompensated hepatitis B cirrhosis took ETV 0.5 mg/d orally for 96 weeks.Supportive and symptomatic treatments were given if necessary.The changes were observed at the 12,24,48 and 96 weeks,including virological and biochemical indicators,PTA and Child-Pugh score.Results Clinical index improv... |
| |
| Keywords: | Hepatitis B Decompensated cirrhosis Entecavir |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
|
